Organization
KP Pharmaceuticals LLC
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
KP Pharmaceuticals LLC
... Pharmaceuticals, Mr. Golubieski was Senior Vice President, Financial Planning & Analysis of King Pharmaceuticals until its acquisition by Pfizer for approximately $3.6 billion. Prior to ...
... Head of Licensing and Business Development for Meridian's former parent company, King Pharmaceuticals, Inc., until its acquisition by Pfizer in 2011. Previous to joining King ...
... to block a competitor. At the time, Meridian and its owner, Tennessee-based King Pharmaceuticals, were producing the EpiPen for Dey, a subsidiary of Merck KGaA, ...
... through a series of its own acquisitions. The firm was purchased by King Pharmaceuticals in 2003; King was acquired by Pfizer in 2011. And that's ...
... Schulman, accusing them of illegally trading in advance of the acquisition of King Pharmaceuticals in 2010. Mr. Schulman represented the company in patent litigation and ...
... tenacious people," according to John Gregory, who served as CEO of King Pharmaceuticals Inc. when Ernie was on its board in the 1990s and when ...
... Imcor Pharmaceutical - Immunomedics - Insight Agents - Jiangsu Hengrui Medicine - King Pharmaceuticals - Lantheus Medical Imaging - Macrocyclics - MDS Nordion - Nanopet ...
... dpiX -- FluoroPharma Medical -- GE Healthcare -- Johnson & Johnson -- King Pharmaceuticals -- Lantheus Medical Imaging -- LipScience -- Medison America -- Molecular ...
... used in the manufacture of the licensed drug candidates. In 2005, King Pharmaceuticals, Inc. entered into an agreement with Pain Therapeutics to develop and commercialize ...
... Tennessee. The lawsuit claims that Mutual Pharmaceutical Company, Inc. conspired with King Pharmaceuticals, Inc. to prevent and delay generic competition to King's brand-name drug, Skelaxin, ...
... amount is equal to the $34 million he's donated to charity since King Pharmaceuticals' buyout of his company. The New York Times piece offers a ...
... his fortune when he sold Jones Pharma, a niche drug company, to King Pharmaceuticals for $3.4 billion in 2000, is under no illusions that a ...
... a Settlement has been reached in a class action lawsuit claiming that King Pharmaceuticals conspired to prevent and delay generic competition to its brand-name drug, ...
... which is designed to discourage common methods of tampering. In 2005, King Pharmaceuticals, Inc. entered into an agreement with Pain Therapeutics, Inc. to develop and ...
... insider trading ahead of Pfizer Inc.'s 2010 $3.6 billion acquisition of King Pharmaceuticals Inc. According to the SEC, the broker, Tibor Klein, allegedly obtained and ...
... S&P 500 index of approximately 40% Brian Markison - Former CEO of King Pharmaceuticals Delivered revenue and EBITDA growth of 36% and 42%, respectively Delivered ...
... and biotech companies, including having served as Chairman of the Executive Committee of Medco Research, a NYSE-listed company that was subsequently acquired by King Pharmaceuticals. ...
... their Form 10-Q filing. Pfizer's disclosure is as follows: "In 2005, King Pharmaceuticals, Inc. (King) entered into an agreement with Pain Therapeutics, Inc. (PT) to ...
... prevent regulatory approval or commercialization. Ligand may also have indemnification obligations to King Pharmaceuticals or Eisai in connection with the sales of the Avinza and ...
... when Mylan Laboratories Inc. said its pending $4 billion acquisition of King Pharmaceuticals Inc. was unlikely to materialize. A statement from Pittsburgh-based Mylan on Wednesday ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤